Disclosure Results

Cyramza **European Marketing Authorisation Holder: Eli Lilly Nederland B.V.**

phase	total complete by 31 July 2016	un-evaluable	evaluable	disclosed in 12 month timeframe	disclosed percentage at 12 months	complete by 31 July 2016	disclosed at 31 July 2016	disclosure percentage at 31st July 2016
phase I & II	26	1	25	24	96%	25	24	96%
phase III	6	0	6	6	100%	6	6	100%
phase IV	0	0	0	0		0	0	
other	0	0	0	0		0	0	
total	**32**	**1**	**31**	**30**	**97%**	**31**	**30**	**97%**

Footnote (company communication): One phase II trial (conducted in the US and Canada) remained undisclosed at 31 July 2016 but has since been published.

Key to columns in table above:

total complete by 31 July 2016 = total number of company-sponsored trials identified which were completed by 31 July 2016
unevaluable = trials with completion date within the last 12 months, or key dates missing - excluded from the analysis
evaluable = trials with all criteria present including dates; hence the base number of trials evaluated for the assessment
disclosed in 12 month timeframe = evaluable trials which were disclosed within the target 12 months*
disclosed percentage at 12 months = proportion of evaluable trials which were disclosed within 12 months*
complete before 31 July 2016 = number of evaluable trials completed before 31 July 2016
disclosed at 31 July 2016 = number of evaluable trials with results disclosed by 31 July 2016
disclosure percentage at 31 July 2016 = proportion of evaluable trials which were disclosed by 31 July 2016

[* 12 months measured from the later of: the first date of regulatory approval (in Europe or the US) or the trial completion date]